AzTrials
AzTrials

MDSPhase 1LDE255NCT02323139

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

A Phase 1 study testing Azacitidine and LDE255 in people with MDS, run by Groupe Francophone des Myelodysplasies at 24 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a phase Ib add-on study of the combination of LDE255 to azacitidine in patients without marrow response after at least 6 cycles of azacitidine. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
MDS
What is being tested?
Azacitidine and LDE255
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
24 sitesFrance
Study dates
10 Feb 2015to 1 Aug 2018
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • High risk myelodysplastic syndrome (MDS) according to International Prognosis Scoring System (IPSS) or acute myeloid leukemia (AML) with low blast count (Bone marrow blast count between 20 and 30%) or non proliferative chronic myelomonocytic leukemia (CMML) (White blood cell (WBC) below 13 G/L)
  • Age over 18 years
  • Performance Status 0 to 2
  • Patient must have recovered from toxicities of any prior treatment regimen (no common toxicity criteria for adverse events (CTCAE)) grading over 1 for non-hematological toxicities, return to baseline for hematological values)
  • Patient must have been treated with azacitidine single agent for at least 6 cycles
  • According to International working group (IWG) 2006 criteria, patient may have a/ stable disease, OR b/ disease progression limited to patients with loss of hematological improvement without bone marrow progression. Patients with bone marrow progression (i.e. increased bone marrow blast count of 50% or more) should not be included.
Show all 15Show fewer
  • Bone marrow blast count should be 10% to 30%
  • Adequate liver and renal function:
  • Serum creatinine less than 1.5 x the institutional upper limit of normal (ULN)
  • Total bilirubin less than 1.5 x the ULN unless considered due to Gilbert's syndrome
  • Alanine aminotransferase (ALT, SGPT), or aspartate aminotransferase (AST, SGOT) less than 2.5 x the ULN unless considered due to organ leukemic involvement
  • Creatine Kinase less than 1.5 x the ULN
  • Able to understand and sign the written informed consent
  • Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatment
  • Men must agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 3 months after the end of treatment if their partner is of childbearing potential.

Who cannot join

  • Allogeneic stem cell transplantation (SCT) within the last 4 months and/or active graft versus host disease (GVHD), or autologous SCT within the last 4 weeks. Patient suitable for allogeneic transplantation and with an identified allogeneic donor (Extension phase only).
  • Active central nervous system (CNS) leukemic involvement.
  • Major surgery within 2 weeks of initiation of study medication.
  • Concurrent uncontrolled medical conditions that may interfere or potentially affect the interpretation of the study.
  • Unable to take oral drugs, or lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes.
  • Patients with unresolved diarrhea > CTCAE grade 2.
Show all 39Show fewer
  • Patients who have previously been treated with systemic LDE225 or with other Hh pathway inhibitors.
  • Patients who have neuromuscular disorders (i.e. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) inhibitors (statins), clofibrate and gemfibrozil. Pravastatin may be used if necessary, with extra caution.
  • Patients who are planning on embarking on new physical activities, such as strenuous exercise, that can result in significant increases in plasma creatine kinase levels while on study treatment. Strenuous muscular activity MUST be avoided within 1 week of blood tests during the study.
  • Patient has history of cardiac dysfunction including any of the following:
  • Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of life ventricular ejection fraction (LVEF) function within the last six months.
  • History of documented congestive heart failure (New York Association functional classification III-IV).
  • Documented cardiomyopathy.
  • Familial history of long QT syndrome.
  • Patient has active cardiac disease including any of the following:
  • Corrected QT (QTc) interval corrected for heart rate using Fridericia's formula (QTcF) > 450 msec for males and > 470 msec for females on the screening electrocardiogram (ECG).
  • Angina pectoris that requires the use of anti-anginal medication.
  • Ventricular arrhythmias except for benign premature ventricular contractions.
  • Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication.
  • Conduction abnormality requiring a pacemaker.
  • Valvular disease with documented compromise in cardiac function.
  • Symptomatic pericarditis.
  • Use of other investigational drugs within 30 days or 5 half-lives of initiation of study medication, whichever is longer.
  • Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of cytochrome P450 (CYP)isoenzyme 3A4/5 (CYP3A4) or drugs metabolized by CYP isoenzyme 2B6 (CYP2B6) or CYP isoenzyme 2C9 (CYP2C9) that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A4/5 inducers for at least 2 weeks prior to starting treatment with LDE225.
  • Patients are excluded if the use of warfarin (substrate of CYP2C9) is necessary and cannot be substituted since LDE225 is competitive inhibitor of CYP2C9 based on in vitro data.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5 milli-International Unit (mIU)/mL).
  • Patients who are not willing to apply highly effective contraception during the study and through the duration as defined below after the final dose of study treatment.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use highly effective contraception during the study and through 6 months after the final dose of study treatment. Highly effective contraception is defined as either:
  • Total abstinence: When this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (i.e., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • Sterilization: Patient has had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
  • Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). [For female study patients, the vasectomised male partner should be the sole partner for that patient].
  • Use a combination of the following (both a+b):
  • Placement of a non-hormonal intrauterine device (IUD) or non-hormonal intrauterine system (IUS).
  • Barrier method of contraception: Condom or Occlusive cap (diaphragm or cervical vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.
  • Note: Hormonal contraception methods (i.e. oral, injected, implanted) are not allowed as it cannot be ruled out that the study drug decreases the effectiveness of hormonal contraception.
  • Note: Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels > 40 mIU/mL and estradiol < 20 pg/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
  • Male patient must use highly effective (double barrier) methods of contraception (i.e., spermicidal gel plus condom) for the entire duration of the study, and continuing using contraception and refrain from fathering a child for 6 months following the study drug. A condom is required to be used also by vasectomized men in order to prevent delivery of the study treatment via seminal fluid.
  • Known human immunodeficiency virus (HIV) positivity.
  • Patients unwilling or unable to comply with the protocol.

Trial locations and contacts

24 sites in 1 country.

24 sites in 1 country

France24 sites

  • CHU d'Amiens

    Amiens, 80054

  • CHU d'Angers

    Angers, 49033

  • CH Henri Duffaut

    Avignon, 84000

  • CH de la Côte Basque

    Bayonne, 64 100

  • Hôpital Avicenne

    Bobigny, 93009

  • Hôpital Henri Mondor

    Créteil, 94010

  • CHU de Grenoble

    Grenoble, 38043

  • CH Le Mans

    Le Mans, 72037

  • IPC-Unité d'Hématologie 3

    Marseille, 13273

  • Centre Hospitalier de Meaux

    Meaux, 77100

  • CHU de Montpellier

    Montpellier, 34295

  • Hôpital Hôtel Dieu

    Nantes, 44093

  • Centre Antoine Lacassagne

    Nice, 06189

  • Hôpital Archet 1

    Nice, 06202

  • CHU de Nîmes

    Nîmes, 30029

  • Hôpital Saint Louis - Service Hématologie Sénior

    Paris, 75010

  • Hôpital Saint-Louis - Service d'hématologie AJA

    Paris, 75010

  • Hôpital Cochin

    Paris, 75014

  • CHU de Haut-Lévèque

    Pessac, 33604

  • CH Lyon Sud

    Pierre-Bénite, 69495

  • CH Annecy Genevois

    Pringy, 74374

  • Hôpital Henri Becquerel

    Rouen, 76038

  • IUC Oncopole - Médecine interne

    Toulouse, 31059

  • CHU Nancy-Brabois

    Vandœuvre-lès-Nancy, 54511

Other trials in France

About this study

Official title: A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

This study is a phase Ib add-on study of the combination of LDE255 to azacitidine in patients without marrow response after at least 6 cycles of azacitidine.

Read the detailed description

Dose escalation of LDE255 will be performed over time using a rolling 6 design to determine the safety of the combination with azacitidine. The starting dose will be 400 mg. Azacitidine will be continued at maximum tolerated dose (MTD). Evaluation will be based on cycle 1 toxicity profile. Once MTD will be determined, 20 additional patients will be treated at recommended dose.

Conditions
MDS
Being tested
Azacitidine and LDE255
Keywords
High risk MDS, Azacitidine, LDE255

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Azacitidine and LDE255Drug

    Also called Vidaza

    Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)

Study groups in NCT02323139
Study groupRoleWhat they receive
Combination of azacitidine and LDE255ExperimentalCombination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
Receives: Drug: Azacitidine and LDE255

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety of the combination assessed by evaluation of hematological and non-hematological toxicities at day 28 of cycle 1

    Measured: 1 month

Secondary outcomes (1)

  1. Clinical efficacy assessed by total percentage of responses, including all patients achieving CR, PR, marrow CR or hematologic improvement, evaluated according to IWG 2006 criteria after 6 treatment cycles

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2014 (estimated)
  2. Study start10 Feb 2015
  3. Primary completionJan 2018
  4. Study completion1 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02323139
Sponsor's protocol ID
GFM-AZA-LDE
Other IDs
2013-003108-38
Acronym
LDE255
Status last verified
Dec 2018
First submitted
26 May 2014
Last updated
6 Dec 2018
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Azacitidine and LDE255 in people with MDS, run by Groupe Francophone des Myelodysplasies at 24 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 24 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety of the combination assessed by evaluation of hematological and non-hematological toxicities at day 28 of cycle 1 (time frame: 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02323139.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in